Author:
Wani Mohmmad Younus,Malik Manzoor Ahmad
Reference117 articles.
1. Schilling T, Keppler KB, Heim ME, Niebch G, Dietzfelbinger H, Rastetter J, Hanauske AR (1996) Clinical phase I and pharmacokinetic trial of the new Titanium complex Budotitane. Investig New Drugs 13(4):327–332
2. Heim ME, Flechtner H, Keppler BK (1989) Clinical studies with Budotitane—a new non-platinum metal complex for cancer therapy. In: Baulieu E et al (eds) Ruthenium and other non-platinum metal complexes in cancer chemotherapy, Progress in clinical biochemistry and medicine, vol 10. Springer, Berlin
3. Duan L, Fischer A, Xu Y, Sun L (2009) Isolated seven-coordinate Ru(IV) dimer complex with [HOHOH]− bridging ligand as an intermediate for catalytic water oxidation. J Am Chem Soc 131:10397–10399
4. Abid M, Shamsi F, Azam A (2016) Ruthenium complexes: an emerging ground to the development of metallopharmaceuticals for cancer therapy. Mini-Rev Med Chem 10:772–786
5. Dragutan I, Dragutan V, Demonceau A (2015) Ruthenium complex: the expanding chemistry of the ruthenium complexes. Molecules 20:17244–17274